DharlMorey2
Posted - 1 hour ago
$ATOS 'anti-cancer' activity. Atossa will be the leader in preventing and curing Breast Cancer. Two simultaneous conference presentations (AACR and SABCS) now. AACR Dec. 9, and most presentations for SABCS around the 10/11th of December for presentations. https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-present-poster-z-endoxifen-aacr-special $XBI $DRUG $AMAM $SYRS
Coastalcool
Posted - 3 days ago
@Rookie1979xxx Never confuse the price action with true Valuation.
Example :$harp & $AMAM sub$$ fore BO of 1 $2 billions.
Coastalcool
Posted - 6 days ago
$AMAM $JNJ $TCBP
DharlMorey2
Posted - 1 week ago
$SLS deserves to run 100-200% just on the upcoming catalysts, let's see. Ran to 19.00 previously, and has more juice with the phase-3 study that ran it to 19.00+ last time. So much data coming -- Highbridge added 6 million + shares (not shown below). Those funds are all ready to feed on this BIO BOOM! $XBI $SYRS $AMAM $DRUG
DharlMorey2
Posted - 1 week ago
$SLS Hedge funds loan out the shares cheaply while they hold all the warrants to cover and profit. Now you're beginning to see the game :) Explosive move up coming -- just need the phase-3 and/or phase-2 data catalyst due at any moment. $XBI $DRUG $AMAM $SYRS
cea
Posted - 1 week ago
$SLS What are you talking about @BigBdr1914? $AMAM ceased to exist on 5 March 2024 after being acquired by Johnson & Johnson for around $28 per share. There’s no comparison.
DharlMorey2
Posted - 1 week ago
$ATOS A great find! Also linking the press release on our '5' year patient that had no recurrence of breast cancer -- this is the purpose of the other trials to show that we can replace Tomoxifen with Z-Endoxifen with lower dosages and less side effects. New STANDARD of care coming! - (5 year patient) https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-provides-five-year-z-endoxifen-treatment (Link to article) https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djae280/7887567?rss=1 $XBI $DRUG $AMAM $SMMT
DharlMorey2
Posted - 2 weeks ago
$SLS Highlighting the part i overlooked in my first message. I also think we'll get GPS phase-3 data very soon. Earnings report historically around Nov. 9 -- let's see what happens with election and then if we get the phase-3 data shortly after. $SYRS $DRUG $AMAM $XBI
DharlMorey2
Posted - 2 weeks ago
$SLS "45 mg (Safety Dose) Once a Week of SLS009 Showed a Median Overall Survival (OS) of 5.5 Months vs. <2.5 Months with Standard of Care;" More data/full results coming at ASH conference in December - Press release: https://ir.sellaslifesciences.com/news/News-Details/2024/SELLAS-Life-Sciences-to-Present-at-the-66th-American-Society-of-Hematology-ASH-Annual-Meeting--Exposition-2024/default.aspx - Accepted Abstract: https://ash.confex.com/ash/2024/webprogram/Paper198686.html $XBI $SYRS $AMAM $DRUG
Earth4thewin
Posted - 2 weeks ago
@MadMaverick $ZVSA's sister company $AMAM was at a low of .48 cents before getting bought out by $JNJ for $28 per share 🙏
Earth4thewin
Posted - 2 weeks ago
$ZVSA's sister company $AMAM was at a low of .48 cents before getting bought out by $JNJ for $28 per share 🥱
DharlMorey2
Posted - 2 weeks ago
$ATOS Excellent results, but market didn't budge. Literally a gift for folks to buy into before more detailed results in about 4 weeks. https://finance.yahoo.com/news/atossa-therapeutics-reports-positive-karisma-113000364.html (Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04 $XBI $AMAM $DRUG $SMMT
DharlMorey2
Posted - 2 weeks ago
$ATOS If $AMAM went for 28.00/share for a 1.77Billion valuation on a phase-1 in the breast cancer space, I would expect Atossa with 5 phase-2 studies coming to completion to be well north of 2+ billion. I would say 4+ billion would be fair value. The price is going up for Atossa every day. Atossa has many other intangibles -- connected to Mayo Clinic (Matt Goetz), Karolinski Institute (Per Hall), Cornell, etc. Has several patents on formulation, delivery, etc. I've long called for 2-4 billion for a buyout (16-32 dollars), but I think that price could go up given the legislation for breast density to be reported, and Atossa being the only company I know of (or furthest along) with MBD results due in next 30 days or so. Not to mention we're working with $LLY 's drug on our latest phase-2, and have a fireside chat for a 70,000 patient study utilizing 'AI' (buzzword of the day, but I think AI in biomed is the killer application). We're in a very VERY good place right now -- rockets! $XBI
DharlMorey2
Posted - 2 weeks ago
$SLS Sellas Algorithm says buy on Friday -- shorts need to cover going into every weekend -- keep the pressure on! - Lockout period otherwise expired at 90 days from 31 million dollar financing - Short interest rapidly decreasing https://www.marketbeat.com/instant-alerts/nasdaq-sls-options-data-report-2024-10-27/ - See DD below on upcoming catalysts THIS QUARTER $XBI $AMAM $SYRS $NUTX
DharlMorey2
Posted - 1 month ago
$ATOS 70,000 is no joke for a trial $XBI $AMAM
Earth4thewin
Posted - 1 month ago
@StockAuthority or like $AMAM
SmallCapMultiplier
Posted - 1 month ago
@ElGatoRogo yes, I was sure of $AMAM getting acquired and it got acquired and went up 97%
However I was “sure” that LCID would be able to deliver their predictions and guidance they released but they did not and I lost $25,000
DharlMorey2
Posted - 1 month ago
@CARTE_BLANCHE_DEVEREAUX 10+ is where I think it will stabilize given that it ran to 9.82 previously on smaller results. Given that $AMAM ran to 28.00 on a smaller study (1 billion market cap on a phase-1) that would indeed put Atossa to ~10.00 for the same market cap. Atossa has a massive phase-2 with 275 patients due in Q4, another phase-2 for Z-Endoxifen in the I-Spy2 trial, another 80mg trial, and other combination therapies with Eli Lily's drug. I'm hoping SLS pops first to be honest :)
JeffTheOmega1
Posted - 2 months ago
$GOSS Please keep us based .89/.90 Need to wait for $NVDA squeeze to cash out calls to load more dip $GOSS is a LT hold play for me My next $AMAM $SMMT swing to Valhalla
Monica362
Posted - 2 months ago
@SoldDaPopinski @Vaxylove @BGirl @herbbrooks @VXRT_Squirrel @Sunwell @Nik_CA @7xbagger @OptionPapa $AMAM “got bought by $JNJ for $2B after going 1,007% on a Friday. “
Happy Labor s Day
ALATOM0369
Posted - 2 months ago
$OCGN $AMAM got bought by $JNJ for $2B after going 1,007% on a Friday. I’ve personally experience a 900% gain with $HQGE, it’s impressive. I have the feeling that we are going to jump that high, and even higher. Havagooday Bulls.
B1GCityCat
Posted - 07/30/24
$AMAM $ATOS $IBRX If they need more patients, should we be concerned? 🤔
Bullishbruk
Posted - 07/28/24
$IBRX and $ATOS are bigger than $AMAM which I bought for $1.25 and just not to long ago got BO for $28.00 Made a killing…$$$$$. Been doing this for a few years know a good company when I see one. Patients please! Minimum PT $45 and $26 respectively. GLTL long and strong
tastee435
Posted - 07/24/24
$SILO You are a wise person, not many understand this offering play 👏🏿 ,Still holding...$ALT and $AMAM did the same thing..🚀
tastee435
Posted - 07/23/24
$SILO Loading opportunity, don't miss the boat..! $JNJ ,$AMAM ,$PFE 🚀
DharlMorey2
Posted - 07/22/24
@jajj3a @GPS_OS_21_vs_SOC_5 $TPSTt jumped 2000% in a day, $GLSI 800%, $AMAM around 500% twice in a year, etc. GPS_OS can pump as long as they keep providing facts. Phase-3 data is a big deal imo -- I think we see double-digits. Too much short interest, too many calls open, etc. this will move up fast!
John_D_Stockefeller
Posted - 07/22/24
@John___wick44 So sorry for your many losses. My story, with $HARP and $AMAM both getting bought out at a nice premium on the same day, is different.
bej_trades
Posted - 4 months ago
@BigSpenderr yeah definitely gives me those vibes. $AMAM was probably my biggest $.30s to $4 in 3 hours. Months later got bought out at $28 / share I was long gone by then tho ha cheers bro! 🍻
DharlMorey2
Posted - 4 months ago
I was able to jump into $CADL late which is what I think SLS is going to do. SLS may in a few months also have more of an $AMAM like buyout sort of deal in the works. Last annual general meeting they said they were actively working with Stifel group to get a partnership in place -- let's see.